The (PIONEER) trial evaluating Ayvakit (25mg, qd) + BSC vs PBO + BSC in 212 patients showed rapid, durable & reductions in all measures of pathological mast cell burden, incl. serum tryptase, KIT D816V variant allele fraction and bone marrow mast cells
Clinical benefits in overall symptoms @24wks. with improvements deepening through 48wks. along with improvements on the most sev. symptom & across all individual symptoms measured, improvements in multiple exploratory EPs of QoL, incl. disease-specific & general health status measures were also reported
The therapy showed a favorable safety profile, the SAE rate (5.0% vs 11.3%). Ayvakit was approved in the US for adults with ISM
Ref: PRNewswire | Image: Blueprint Medicines
Related News:- Blueprint Medicines’ Ayvakit (avapritinib) Receives the US FDA’s Approval as the First Treatment for Indolent Systemic Mastocytosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
